Professor & Assoc. Dean of Research
Department of Pharmaceutical Sciences
Cationic antibiotic peptides, inflammation, innate immunity, inflammatory-mediated diseases, atherosclerosis, Alzheimer's disease, bacterial keratitis, sepsis, leukocyte biology, and leukocyte-endothelial interactions.
This laboratory investigates the role of a novel inflammatory mediator known as CAP37. We focus on the significance of this protein in host defense against severe infections including infections of the eye and in various inflammatory mediated diseases such as atherosclerosis and Alzheimer's disease. We currently employ a combination of cellular, immunological, biochemical and molecular approaches at the in vitro and in vivo level to solve these questions. Our long-term goals are to design new and effective antibiotics and anti-inflammatory therapeutics.
Education & Experience
- Postdoctoral fellow/Immunology, Royal Children's Hospital, Melbourne, Australia, 1982-1984.
- Ph.D., Pathology, University of Melbourne, Australia. 1982.
- B.Sc. (Hon), Immunology. University of Melbourne, Australia,1976.
- B.Sc., Microbiology/Pathology. University of Melbourne, Australia, 1975.
- Chair and Chief Scientific Officer, Biolytx Pharmaceuticals Corp, OKC, OK, 2006-present
- President and Chief Scientific Officer, Biolytx Pharmaceutical Corp (commercial development of an antibiotic based on CAP37 peptides for the treatment of severe Gram negative infections), 2005-2006.
- Professor, Dept. of Pathology, 2009.
- Assoc. Professor, Dept. of Pathology, 1997-2009.
- Adjunct Professor, Dept. of Cell Biology, OUHSC, OKC, OK, 2009-present
- Adjunct Assoc. Professor, Dept. of Cell Biology & Surgery, OUHSC, OKC, OK, 1997-2009
- Adjunct Professor, Dept. of Pathology, OUHSC, OKC, OK, 2009-present
- Assistant Professor, Dept. of Pathology, OUHSC, OKC, OK, 1992-1997
- Assistant Professor, Dept. of Microbiology & Immunology, Emory University, Atlanta, GA, 1991-1992
- Senior Research Associate, Dept. of Microbiology & Immunology, Emory University, Atlanta, GA, 1984-1990.
Honors & Service
OUHSC Patent Award, May 2013.
Henry Zarrow Presidential Professorship for meeting the highest standards of excellence in scholarship and teaching, 2008.
Chair, minisymposium "Host pathogen interactions and toll-like receptors." Experimental Biology 2008, San Diego, CA.
Finalist, Grace & Franklin Bernsen Foundation; Most Promising New Business Award to Biolytx Pharmaceuticals Corp., 2007.
"On the brink award winner," Journal Record Innovator of the Year award, 2006.
Co-chair, minisymposium "Innate and acquired immunity," Experimental Biology, 2006, San Francisco, CA.
Discussion Leader, "Vascular Wall," Experimental Biology 2003, San Diego, CA.
Chair, "Mediators of Inflammation," Experimental Biology 2000, San Diego, CA.
- NIH/NEI Anterior Eye Disease study section - ad hoc member, 2008, 2009, 2010.
- NIH Brain Disorders and Clinical Neuroscience (ZRGSBDCN-F02) study section, Oct. 10, 2008.
- American Society for Investigative Pathology (ASIP) Program Committee member for Experimental Biology (EB 2007 & EB 2008).
- NIH, Brain Disorders and Clinical Neuroscience BDCN-3 Study Section - ad hoc reviewer, 2001, 2002
- American Heart Association, National Immunology & Microbiology I Study Section, 1999-2002
- "Method of predicting sepsis or an acute infectious inflammatory response." Patent No. 7,655,480 issued February 2, 2010.
- "Antifungal peptides and methods of use thereof." US 60/704,257 (Pending).
- "Treatment and inhibition of ocular infections and wounds by CAP37 and CAP37 peptides." Patent No. 7,354,900 issued April 8, 2008.
- "Antimicrobial peptides and methods of use thereof." Patent No. 6,730,659 issued May 3, 2004.
- "Antimicrobial peptides and methods of use thereof." Patent No. 6,514,701 issued February 4, 2003.
- "Antimicrobial peptides and methods of use thereof." Patent No. 6,107,460 issued August 22, 2000.
- "Method for treatment of bacterial infections." Patent No. 6,071,879 issued June 6, 2000.
- "Method for inhibiting production of tumor necrosis factor." Patent No. 5,877,151 issued March 2, 1999.
- "Method and composition for the treatment of septic shock." Patent No. 5,650,392 issued July 22, 1997.
- "Method and composition for the treatment of septic shock." Patent No. 5,627,262 issued May 6, 1997.
- "Method and composition for the treatment of septic shock." Patent No. 5,607,916 issued March 4, 1997.
- "Chemotactic, antibiotic and lipopolysaccharide binding peptide fragments of CAP37." Patent No. 5,484,855 issued January 16, 1996.
- "Method of increasing monocyte chemotaxis with CAP37 and monocyte chemotactic portions thereof." Patent No. 5,458,874 issued October 17, 1995.
Selected Publications & Presentations
Pereira HA, Tsyshevskaya-Hoover I, Hinsley H, Logan S, Nguyen M, Nguyen T-T, Pohl J, Wozniak K, Fidel Jr PL. Candidacidal activity of synthetic peptides based on the antibiotic domain of the neutrophil-derived protein, CAP37. Medical Mycology 2010; 48: 263-272.
Gordon YJ, Romanowski GG, Shanks RMQ, Yates KT, Hinsley H, Pereira HA. CAP37-derived antimicrobial peptides has in vitro antiviral activity against adenovirus and herpes simplex virus type 1. Curr Eye Res 2009; 34:241-249.
Pereira HA. Novel therapies based on cationic antimicrobial peptides. Curr Pharm Biotechnol 2006; 7:229-234.
Pereira HA, Ruan X, Gonzalez ML, Hoover I, Chodosh J. Modulation of corneal epithelial functions by the neutrophil-derived inflammatory mediator CAP 37. Invest Ophthalmol Vis Sci 2004; 45: 4284-4292.
Pereira HA, Kumar P, Lerner MR, Brackett DJ. Inducible expression of the inflammatory protein CAP37 in the epidermis during wound healing. Focus on Protein Res 2004; pp. 127-144. Ed. J.W. Robinson.
Current Grants Awarded
Development of an antimicrobial peptide therapeutic for Pseudomonas infections. The major goals of this project are to perform the critical pre-clinical experiments required to advance a novel antibiotic peptide for the treatment of hospital acquired infections into clinical trials. NIH/NIAID 1U01 A1075391, 09/01/07-08/31/12.
CAP37 and ocular inflammation. The major goals of this project are to determine the biological significance of the innate immune system molecular, CAP37, in corneal inflammation and to investigate its therapeutic potential for treatment of corneal wounds and infections. NIH/NEI 1R01 EY 015534-01A2, 09/30/07-08/31/12.
New therapeutics based on a natural antibiotic peptide. The evaluation of a novel antibiotic peptide based on CAP37 to treat serious Gram negative infections and sepsis. OCAST/OARS, 03/01/08-08/31/11.
Molecular basis of immunity. For training graduate students and postdoctoral fellows in immunology. NIH/NIAID IP32-A107633-06 (Cunningham PI), 09/01/06-08/31/11.
New drugs for bad bugs. State of Oklahoma EDGE (Economic Development Generating Excellence) contract with Biolytx.